A Babsky, Ju Shenghong - Apparent diffusion coefficient of waterin evaluation of treatment response in animal body tumors - страница 4
62. Chenevert T.L., Stegman L.D., Taylor J.M. et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J. Natl. Cancer Inst, 2000; 92:
63. Tozer G.M., Kanthou C., Parkins C.S., Hill S.A. The biology of the combretastatins as tumour vasculartargeting agents. Int. J. Exp. Pathol, 2002; 83: 21-38.
64. Welsh S., Williams R., Kirkpatrick L. et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther, 2004; 3:
65. Chinnaiyan A.M., Prasad U., Shankar S. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA, 2000; 97: 1754-1759.
66. Lyseng-Williamson K.A., Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs, 2005; 65: 2513-2531.
67. Chenevert T., McKeever P., Ross B. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin. Cancer. Res, 1997; 3: 1457-1466.
68. Ross B., Chenevert T., Rehemtulla A. Magnetic resonance imaging in cancer research. Eur. J. Cancer, 2002; 38: 2147-2156.
69. Ross B., Moffat B., Lawrence T. et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol. Cancer Ther, 2003; 2: 581-587.
70. Ross B.D., Zhao Y.J., Neal E.R. et al. Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study. Proc. Natl. Acad. Sci. USA, 1998; 95: 7012-7017.
71. Winter P.M., Poptani H., Bansal N. Effects of chemotherapy by 1,3-bis(2-chloroethyl)-1-nitro-sourea on single-quantum- and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance ofthe subcutaneously implanted 9L glioma. Cancer Res, 2001; 61: 2002-2007.
72. Steen R.G., Tamargo R.J., McGovern K.A. et al. In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology. Cancer Res, 1988; 48: 676-681.
73. Steen R.G. Response of solid tumors to chemotherapy monitored by in vivo 31P nuclear magnetic resonance spectroscopy: a review. Cancer Res, 1989; 49: 4075-4085.
74. Ameer G.A., Crumpler E.T., Langer R. Cell-killing potential of a water-soluble radical initiator. Int. J. Cancer, 2001; 93: 875-879.
75. Dzik-Jurasz A., Domenig C., George M. et al. Diffusion MRI for prediction of response of rectal cancerto chemoradiation. Lancet, 2002; 360: 307-308.
76. Mardor Y., Roth Y., Lidar Z. et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res, 2001; 61:4971-4973.
77. Yuan Y.H., Xiao E.H., Liu J.B. et al. Characteristics and pathological mechanism on magnetic resonance diffusion-weighted imaging after chemoembolization in rabbit liver VX-2 tumor model. World J. Gastroenterol, 2007; 13: 5699-5706.
78. Yuan Y.H., Xiao E.H., Liu J.B. et al. Gene expression and MR diffusion-weighted imaging after chemoembolization in rabbit liver VX-2 tumor model. World J. Gastroenterol, 2008; 14:
79. Momparler R.L., Karon M., Siegel S.E., Avila F. Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res, 1976; 36: 2891-2895.
80. Kim H., Morgan D.E., Buchsbaum D.J. et al. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res, 2008; 68: 8369-8376.
81. Jennings D., Hatton B.N., Guo J. et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia, 2002; 4: 255-262.
82. Vogel-Claussen J., Gimi B., Artemov D., Bhujwalla Z.M. Diffusion-weighted and macromo-lecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126. Cancer Biol. Ther, 2007; 6: 1469-1475.
83. Micheletti G., Poli M., Borsotti P. et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res, 2003; 63: 1534-1537.
84. Dev S.B., Caban J.B., Nanda G.S. et al. Magnetic resonance studies of laryngeal tumors implanted in nude mice: effect of treatment with bleomycin and electroporation. Magn. Reson. Imaging, 2002; 20: 389-394.
85. Kamm Y.J., Heerschap A., Rosenbusch G. et al. 5-Fluorouracil metabolite patterns in viable and necrotic tumor areas of murine colon carcinoma determined by 19F NMR spectroscopy. Magn. Reson. Med, 1996; 36: 445-450.
86. Koh D.M., Scurr E., Collins D. et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am. J. Roentgenol, 2007; 188:
87. Poptani H., Bansal N,. Graham R.A. et al. Detecting early response to cyclophosphamide treatment of RIF-1 tumors using selective multiple quantum spectroscopy (SelMQC) and dynamic contrastenhanced imaging. NMR Biomed,2003; 16: 102-111.
Біологічні Студії / Studia Biologica • 2009 • Том 3/№1 • С. 3-24
 tumors  and with the decrease in tumor cell density in 9L glioma . 5FU-treat-ment of RIF-1 tumors also led to increase in ECS. The ratio of necrotic to total tumor area in histological sections was 52% higher than to controls three days after the treatment. Furthermore, cellular density was 26% lower in necrotic areas of the treated tumors . In necrotic areas of tumors, much evidence of apoptotic and necrotic change was found, such as dusting nuclei, pyknosis, neutrophil invasion, and/or karyorrhexis.
Thoeny et al. used a rhabdomyosarcoma tumor model to study the effects of the vascular targeting agent combretastatin A4 on waterADC using a 1.5 T MR system [19, 43, 49]. Combretastatin A4 produces a reversible disruption of the vascular network in tumors causing cell death without damaging the vasculature of normal organs . The authors proposed that the difference between the ADC values calculated using low b-values of 0, 50, and 100 s/mm2 (ADClow) and high b-values of 500, 750, and 1,000 s/mm2 (ADChi h) provides information about the perfusion component in ADC (ADCperf) . They showed that treatment of sc-implanted rhabdomyosarcoma with a singlePip dose of 25 mg/kg combretastatin A4 leads to significant decreases in ADClow, ADChigh, and ADCperf 1 and 6 hr post-treatment and is associated with tumor growth delay. However, two and nine days after combrestatin A4 injection when the tumor growth delay turned up to significant growth, ADClowand ADChigh started to increase overlapping the before treatment values. ADCperfwas still lower on day 2 but increased on day 9 compared to the before treatment value. The changes in ADCperf were correlated with the volume transfer constant k (R2 = 0.46) and the initial slope (R2 = 0.67) calculated from perfusion data using dynamic contrast-enhanced MRI. The changes of mean ADC from the entire rhabdomyosarcoma showed similar trend to the ADChi h changes . Thus, total tumor ADC showed an early decrease after combretastatin A4 injection from 1.26x10-3 mm2/s (before) to 1.18x10-3 mm2/s (1 hr) and 1.08x10-3 mm2/s (6 hr), histologically corresponding to vessel congestion and vascular shutdown in periphery but no necrosis. An increase of total tumor ADC (1.79x10-3 mm2/s) 2 days after the drug injection was associated with progressive necrosis and a significant decrease 9 days after treatment (1.41x10-3 mm2/s) corresponded to tumor re-growth. Repeated combretastatin A4 administration at a dose of 25 mg/kg injected with an interval period of nine days retains efficacy in rat rhabdomyosarcomas, with similar effects on waterADC after each drug administration . The authors concluded that both DW and dynamic contrast-enhanced MRIs provide information about intratumoral cell viability and necrosis and allow monitoring of perfusion changes after administration ofvascular targeting agents.
Thoeny H.C., De Keyzer F. Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur. Radiol, 2007; 17: 1385-1393.
Walker M.D., Alexander E., Jr., Hunt W.E. et al. Evaluation of BCNU and/or radiotherapy in the treatment ofanaplastic gliomas. A cooperative clinical trial. J. Neurosurg, 1978; 49: 333-343.